ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  New England Journal of Medicine

• Publication date

  2013-08-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMoa1213299PMID 23924003PMCID PMC3943357
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study.

  2012cited by this paper
• Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning.

  2012cited by this paper
• Steroid-refractory acute GVHD: lack of long-term improved survival using new generation anticytokine treatment.

  2012cited by this paper
• What predicts high risk acute graft‐versus‐host disease (GVHD) at onset?: identification of those at highest risk by a novel acute GVHD risk score

  2012cited by this paper
• First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.

  2012cited by this paper
• Prognostic value of response after upfront therapy for acute GVHD

  2012cited by this paper
• Risk factors for acute GVHD and survival after hematopoietic cell transplantation.

  2012cited by this paper
• Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers

  2011cited by this paper
• Interleukin-1 in the pathogenesis and treatment of inflammatory diseases.

  2011cited by this paper
• Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease.

  2011cited by this paper
• Steroid-Refractory Acute GVHD: Predictors and Outcomes

  2011cited by this paper
• Discovery and validation of graft-versus-host disease biomarkers.

  2011cited by this paper
• The best endpoint for acute GVHD treatment trials.

  2010cited by this paper
• Graft-versus-host disease treatment: predictors of survival.

  2010cited by this paper
• Elafin Is a Biomarker of Graft-Versus-Host Disease of the Skin

  2010cited by this paper
• Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer

  2010cited by this paper
• Reduced mortality after allogeneic hematopoietic-cell transplantation.

  2010cited by this paper
• Graft-versus-host disease.

  2009cited by this paper
• Initial Liver Involvement in Acute GVHD is Predictive for Nonrelapse Mortality

  2009cited by this paper
• A biomarker panel for acute graft-versus-host disease.

  2009cited by this paper
• IL-33 Induces Antigen-Specific IL-5+ T Cells and Promotes Allergic-Induced Airway Inflammation Independent of IL-41

  2008cited by this paper
• IL-33 induced Ag-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4

  2008cited by this paper
• IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system.

  2007cited by this paper
• Soluble ST2 Blocks Interleukin-33 Signaling in Allergic Airway Inflammation*

  2007cited by this paper
• Management of acute graft‐versus‐host disease

  2007cited by this paper
• Contribution of protein fractionation to depth of analysis of the serum and plasma proteomes.

  2007cited by this paper
• Quantitative analysis of acrylamide labeled serum proteins by LC-MS/MS.

  2006cited by this paper
• IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines.

  2005cited by this paper
• Expression and function of the ST2 gene in a murine model of allergic airway inflammation

  2002cited by this paper
• Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems.

  2002cited by this paper
• Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop.

  2001cited by this paper
• A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease.

  2000cited by this paper
• A Proportional Hazards Model for the Subdistribution of a Competing Risk

  1999cited by this paper
• T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function.

  1998cited by this paper
• Selective Expression of a Stable Cell Surface Molecule on Type 2 but Not Type 1 Helper T Cells

  1998cited by this paper
• The expression of ST2 gene in helper T cells and the binding of ST2 protein to myeloma-derived RPMI8226 cells.

  1997cited by this paper
• Expression of ST2, an interleukin-1 receptor homologue, is induced by proinflammatory stimuli.

  1997cited by this paper
• Secreted and membrane-bound isoforms of T1, an orphan receptor related to IL-1-binding proteins, are differently expressed in vivo.

  1995cited by this paper
• 1994 Consensus Conference on Acute GVHD Grading.

  1995cited by this paper

• Assessing the Clinical Performance of a Presymptomatic Acute Graft-Versus-Host Disease Biomarker Test in Hematopoietic Stem Cell Transplant Recipients.

  2026cites this paper
• The BIOPREVENT machine-learning algorithm predicts chronic graft-versus-host disease and mortality risk using posttransplant biomarkers

  2026cites this paper
• Clinical correlation between plasma biomarker levels and post-transplant complications of allogeneic hematopoietic stem cell transplantation in children.

  2026cites this paper
• A Study of Epidermal Elafin Immunohistochemistry as a Diagnostic Biomarker of Acute Skin GVHD

  2026cites this paper
• Percentage of CD56+ monocytes at neutrophil engraftment is associated with the incidence of acute graft-versus-host disease

  2026cites this paper
• Autonomous artificial intelligence prescribing a drug to prevent severe acute graft-versus-host disease in HLA-haploidentical transplants

  2025cites this paper
• Relevant biomarkers in acute graft-versus-host disease secondary to transplantation of hematopoietic stem cells.

  2025cites this paper
• The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD

  2025cites this paper
• Increased Plasma ST2 Levels Precede the Development of Severe Acute GvHD and Chronic GvHD After Pediatric Hematopoietic Stem Cell Transplantation

  2025cites this paper
• Evaluation of the role of serum soluble ST2 as a diagnostic biomarker for cancer-associated venous thromboembolism

  2025cites this paper
• Blood proteomics for quantitative biomarkers of cellular therapies

  2025cites this paper
• Phase 1/2 Study of High-Dose Palifermin for GVHD Prophylaxis in Patients Undergoing HLA-Matched Unrelated Donor HCT.

  2025cites this paper
• Pre-transplant inflammation and its associations with acute GvHD and mortality in pediatric allogeneic hematopoietic stem cell transplantation patients

  2025cites this paper
• Bronchial structural changes analyzed with three-dimensional computed tomography correlate with severe acute graft-versus-host disease after allogenic hematopoietic stem cell transplantation

  2025cites this paper
• Utilization of Clinical Data and Evaluation of Biomarkers in the Investigation of Graft-Versus-Host Disease Outcomes.

  2025cites this paper
• DecodingAcute GVHD: The role of serum biomarkers and imaging in diagnosis and management.

  2025cites this paper
• Leucine-rich α-2 glycoprotein 1 (LRG1) during inflammatory complications after allogeneic stem cell transplantation and CAR-T cell therapy

  2025cites this paper
• Soluble ST2 as a Predictive Biomarker for Acute Graft‐Versus‐Host Disease Post ‐Allogeneic Stem Cell Transplantation

  2025cites this paper
• Endothelial activation and stress index (EASIX) as a biomarker to predict ruxolitinib failure for steroid‐refractory acute graft‐versus‐host disease treatment

  2025cites this paper
• Plasma nucleosome levels and risk of acute graft-versus-host disease after myeloablative allogeneic hematopoietic stem cell transplantation: a single-center cohort study.

  2025cites this paper
• Belumosudil reduces oral chronic graft-versus-host disease tissue inflammation and fibrosis: a ROCKstar companion study

  2025cites this paper
• Oral beclomethasone dipropionate therapy and prognostic plasma biomarkers for gastrointestinal graft-versus-host disease

  2025cites this paper
• Biochemical markers and emerging therapies for intestinal manifestation of graft-versus-host disease

  2025cites this paper
• Leukemia inhibitory factor (LIF) in acute graft-versus-host disease: A hypothesis-generating review.

  2025cites this paper
• Age-enhanced MAGIC algorithm predicts mortality in pediatric aGVHD: a multicenter study

  2025cites this paper
• Immune Monitoring after Cell Therapy and Hematopoietic Cell Transplantation: Guidelines by the ISCT Stem Cell Engineering Committee

  2025cites this paper
• Prediction and Prognostication of Acute Graft‐Versus‐Host Disease by MAGIC Biomarkers

  2025cites this paper
• A randomized controlled trial of conventional GVHD prophylaxis with or without teprenone for the prevention of severe acute GVHD

  2025cites this paper
• Navigating Challenges of aGvHD Predictive Biomarkers in αβhaplo-HSCT Recipients: Still Waiting for MAGIC to Happen.

  2025cites this paper
• Using Machine Learning to Predict Acute Graft‐Versus‐Host Disease in Pediatric Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Integration of Clinical and Genetic Factors

  2025cites this paper
• Validation of Manhattan risk to predict aGvHD severity in Rapamycin and PTCy-based prophylaxis: a study on 459 consecutive HCT patients

  2025cites this paper
• Ruxolitinib plus steroids for acute graft versus host disease: a multicenter, randomized, phase 3 trial

  2024cites this paper
• Future biomarkers for acute graft-versus-host disease: potential roles of nucleic acids, metabolites, and immune cell markers

  2024cites this paper
• Serum 5-S-cysteinyldopa as a predictive biomarker for stem cell transplantation-related complications in children and young adults

  2024cites this paper
• Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD

  2024cites this paper
• Ruxolitinib for the treatment of acute graft-versus-host disease: a retrospective analysis

  2024cites this paper
• Repeated Infusions of Bone-Marrow-Derived Mesenchymal Stem Cells over 8 Weeks for Steroid-Refractory Chronic Graft-versus-Host Disease: A Prospective, Phase I/II Clinical Study

  2024cites this paper
• Studies of Structure-Activity Relationship of 2-(Pyrrolidin-1ylmethyl)-1H-pyrrole-Based ST2 Inhibitors and Their Inhibition of Mast Cells Activation.

  2024cites this paper
• Investigation of biomarkers to predict outcomes in allogeneic hematopoietic stem cell transplantation.

  2024cites this paper
• Graft-Versus-Host Disease: Can Biomarkers Assist in Differential Diagnosis, Prognosis, and Therapeutic Strategy?

  2024cites this paper
• A More MAGICal Alogrithm in Acute GVHD.

  2024cites this paper
• Early inflammatory markers as prognostic indicators following allogeneic stem cell transplantation

  2024cites this paper
• Unlocking protein-based biomarker potential for graft-versus-host disease following allogenic hematopoietic stem cell transplants

  2024cites this paper
• ST2 and Reg3α: Can they predict aGvHD, steroid refractoriness and transplant-related mortality in pediatric patients after HSCT?

  2024cites this paper
• High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention

  2024cites this paper
• A tissue-intrinsic IL-33/EGF circuit promotes epithelial regeneration after intestinal injury

  2023cites this paper
• Early View

  2023cites this paper
• Novel therapies for graft versus host disease with a focus on cell therapies

  2023cites this paper
• Prophylactic Mitigation of Acute Graft versus Host Disease by Novel 2-(Pyrrolidin-1-ylmethyl)pyrrole-Based Stimulation-2 (ST2) Inhibitors.

  2023cites this paper
• Multimodal immune cell phenotyping in GI biopsies reveals microbiome-related T cell modulations in human GvHD

  2023cites this paper
• Pretransplant EASIX score predicts non-relapse and overall mortality of adult patients undergoing single-unit unrelated cord blood transplantation.

  2023cites this paper
• Combination of ST2 With Organ-Specific Biomarker is More Sensitive and Specific for the Diagnosis of Acute Graft-vs-Host Disease.

  2023cites this paper
• The MAGIC algorithm probability (MAP)‐guided preemptive therapy of acute graft versus host disease with methylprednisolone: A randomized controlled trial

  2023cites this paper
• Acute graft-versus-host disease

  2023cites this paper
• Prospective assessment of risk biomarkers of sinusoidal obstruction syndrome after hematopoietic cell transplantation

  2023cites this paper
• Validated graft-specific biomarkers identify patients at risk for chronic graft-versus-host disease and death

  2023cites this paper
• Expansion of ST2-expressing macrophages in a patient with bronchiolitis obliterans syndrome

  2023cites this paper
• Prognostic value of blood biomarkers in steroid-refractory or steroid-dependent acute graft-versus-host disease: a REACH2 analysis

  2023cites this paper
• Fecal Microbiota Transplantation for Acute Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation: Expanding the Horizon into Pediatrics.

  2023cites this paper
• EASIX score predicts inferior survival after allogeneic hematopoietic cell transplantation

  2023cites this paper
• Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study

  2023influential citation
• EASIX SCORE CORRELATES WITH ENDOTHELIAL DYSFUNCTION BIOMARKERS AND PREDICTS RISK OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC TRANSPLANTATION.

  2023cites this paper
• Data-driven grading of acute graft-versus-host disease

  2023influential citation
• Biomarkers for early complications post hematopoietic cell transplantation: Insights and challenges

  2023influential citation
• Reeling in complement in transplant‐associated thrombotic microangiopathy: You're going to need a bigger boat

  2023cites this paper
• Intestinal permeability in patients undergoing stem cell transplantation correlates with systemic acute phase responses and dysbiosis

  2023cites this paper
• Hepatic graft-versus-host disease: What we know, when to biopsy, and how to diagnose.

  2023cites this paper
• Unveiling amphiregulin: a blood-based biomarker for graft-versus-host disease risk assessment and monitoring.

  2023cites this paper
• Current Advances in Graft-versus-host Disease After Intestinal Transplantation

  2023cites this paper
• Current Prophylaxis and Treatment Approaches for Acute Graft-Versus-Host Disease in Haematopoietic Stem Cell Transplantation for Children With Acute Lymphoblastic Leukaemia

  2022cites this paper
• Thrombospondin-1, Platelet Factor 4, and Galectin-1 are Associated with Engraftment in Patients with Sickle Cell Disease Who Underwent Haploidentical HSCT.

  2022cites this paper
• A biomarker panel for risk of early respiratory failure following hematopoietic cell transplantation

  2022cites this paper
• Severe testing with high-dimensional omics data for enhancing biomedical scientific discovery

  2022cites this paper
• Role of endothelial cells in graft-versus-host disease

  2022influential citation
• Stem Cell Therapy and Innate Lymphoid Cells

  2022cites this paper
• Statin‐based endothelial prophylaxis and outcome after allogeneic stem cell transplantation

  2022cites this paper
• Kidney Disease Following Hematopoietic Stem Cell Transplantation.

  2022cites this paper
• Pre-Transplantation Plasma ST2 Level as a Prognostic Biomarker of 1-Year Non-Relapse Mortality in Allogeneic Hematopoietic Cell Transplantation.

  2022cites this paper
• Current Definitions and Clinical Implications of Biomarkers in Graft Versus Host Disease.

  2022cites this paper
• Structure-Activity relationship of 1-(Furan-2ylmethyl)Pyrrolidine-Based Stimulation-2 (ST2) inhibitors for treating graft versus host disease.

  2022cites this paper
• Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tract

  2022cites this paper
• Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification

  2022cites this paper
• Prospective external validation of biomarkers to predict acute graft-versus-host disease severity

  2022cites this paper
• General Rehabilitation Program after Knee or Hip Replacement Significantly Influences Erythrocytes Oxidative Stress Markers and Serum ST2 Levels

  2022cites this paper
• How We Prevent GVHD in High Risk Patients: Post Transplant Cyclophosphamide and Beyond.

  2022cites this paper
• Evaluating immune response and metabolic related biomarkers pre-allogenic hematopoietic stem cell transplant in acute myeloid leukemia

  2022influential citation
• Computational Cosolvent Mapping Analysis Leads to Identify Salicylic Acid Analogs as Weak Inhibitors of ST2 and IL33 Binding.

  2022cites this paper
• Current status of clinical trials assessing mesenchymal stem cell therapy for graft versus host disease: a systematic review

  2022cites this paper
• Acute graft-versus-host disease increase risk and accuracy in prediction model of transplantation-associated thrombotic microangiopathy in patients with myelodysplastic syndrome

  2022cites this paper
• Graft-versus-host disease: establishing IL-33 as an important costimulatory molecule

  2022cites this paper
• Non-Invasive Diagnosis of Pediatric Intestinal Graft-Versus-Host Disease: A Case Series

  2022cites this paper
• Single Nucleotide Polymorphisms of IL-33 Gene Correlated with Renal Allograft Fibrosis in Kidney Transplant Recipients

  2021cites this paper
• Elevated REG3α predicts refractory aGVHD in patients who received steroids-ruxolitinib as first-line therapy

  2021cites this paper
• Antigen-specific T cell responses correlate with decreased occurrence of acute GVHD in a multicenter contemporary cohort

  2021cites this paper
• Early Myeloid Derived Suppressor Cells (eMDSCs) Are Associated With High Donor Myeloid Chimerism Following Haploidentical HSCT for Sickle Cell Disease

  2021cites this paper
• T Cell Subsets in Graft Versus Host Disease and Graft Versus Tumor

  2021cites this paper
• Evaluation of elafin as a prognostic biomarker in acute graft-versus-host disease.

  2021cites this paper
• Biomarkers of graft-vs-host disease: Understanding and applications for the future

  2021cites this paper
• New therapeutic targets and biomarkers for acute graft-versus-host disease (GVHD)

  2021cites this paper
• Acute GVHD, BK virus hemorrhagic cystitis and age are risk factors for transplant-associated thrombotic microangiopathy in adults

  2021influential citation